10/5/2995 IAP20 Recionario 22 MAR 2006 Docket No.: 59755US(49949) (PATENT)

Confirmation No.: N/A

Examiner: Not Yet Assigned

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US) (National Phase of International Appln.: PCT/US04/031412 Publication No. WO2005/030222 A1)

In re Patent Application of: Milan R. Uskokovic, et al.

International Application No.: PCT/US04/031412

International Filing Date: September 24, 2004

Filed: Concurrently Herewith Art Unit: N/A

For: 1,3-DIACYLATED, 26, 27-

ALKYL/HALOALKYL VITAMIN D3 COMPOUNDS AND METHODS OF USE

THEREOF

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have



U.S. National Phase Application of PCT/US04/031412 IDS

Attorney Docket No. 59755US(49949)

AP20 REGUPTIFIO 22 MAR 2006.

previously been transmitted by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent application No. PCT/US04/031412, filed September 24, 2004. A copy of the International Search Report is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants submit that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62138US(49949). A duplicate copy of this paper is enclosed.

Dated: March 22, 2006

Peter C. Lauro, Esq.

Respectfully submitted

Registration No.: 32,360

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known 7 0 0 4 5		
		_		Application Number	Not Assigned	
IN	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	Concurrently Herewith	
S				First Named Inventor	Milan R. Uskokovic	
				Art Unit	N/A	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	59755US(49949)	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA**	US-5,665,387	09-09-1997	MATHIEU et al		
	AB**	US-6,492,353-B1	12-10-2002	MANCHAND et al		

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA**	-WO 02/094247-A2	05-10-2002	ADORINI et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA**	MATHIEU et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia (1994) 37, pages 552-558	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered
0101101010	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.